HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership and institutional investors. The company plans to use the proceeds to fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and for general corporate purposes.
HeartBeam is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The Company holds over 20 issued patents related to technology enablement. The successful closing of this offering provides HeartBeam with additional capital to advance its innovative technologies and expand its market presence.
For more details on the offering, view the full press release at https://ibn.fm/9iNYY. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
This announcement is significant as it underscores HeartBeam’s commitment to commercializing its FDA-cleared technologies and expanding its product pipeline. The funding will enable the company to accelerate the adoption of its cable-free, 3D ECG technology, which has the potential to improve cardiac care by allowing remote monitoring and early detection of heart conditions. With over 20 issued patents, HeartBeam is well-positioned to innovate in the cardiac monitoring space.
